Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs
Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs
复制标题
DOI：
10.1007/s00774-018-0955-7
复制
发表时间：
2019-05-01
影响因子：
3.3
通讯作者：
Kawakami, Atsushi
中科院分区：
文献类型：
--
作者：
Iwamoto, Naoki;Okamoto, Momoko;Kawakami, Atsushi
我们通过测量患者的腰部骨密度（BMD）和骨转换标志物，检查了狄诺塞麦治疗糖皮质激素诱导的骨质疏松症（GIOP）合并风湿病患者的有效性和安全性。共有 66 名连续患者在 2013 年 7 月至 2016 年 8 月期间开始接受狄诺塞麦治疗，并进行了为期 12 个月的评估。所有患者均因潜在风湿性疾病接受糖皮质激素治疗。临床评估包括通过双能X射线吸收测量技术测量腰椎（L2-L4）的BMD，以及基线、开始狄诺塞麦治疗后6个月和12个月时的骨转换标志物尿中1型胶原N端肽（NTX）、血清完整原胶原1型N端前肽（P1NP）和骨特异性碱性磷酸酶（BAP）。还分析了 12 个月之前的不良事件 (AE)。从基线到第 6 个月和第 12 个月，BMD 的平均百分比变化显着（增加 2.85%，p
We examined the efficacy and safety of denosumab as treatment for glucocorticoid-induced osteoporosis (GIOP) patients complicated with rheumatic diseases, by measuring patients' lumber bone mineral density (BMD) and bone turnover markers. A total of 66 consecutive patients for whom denosumab was initiated between July 2013 and August 2016 were enrolled and evaluated for 12months. All of the patients were treated with glucocorticoids for underlying rheumatic diseases. The clinical assessment included measurements of the BMD of the lumbar spine (L2-L4) by a dual-energy X-ray absorptiometry technique and the bone turnover markers N-terminal telopeptide of type 1 collagen (NTX) in urine, serum intact procollagen type 1N-terminal propeptide (P1NP), and bone-specific alkaline phosphatase (BAP) at baseline, 6months and 12months after the start of denosumab treatment. Adverse events (AEs) until 12months were also analyzed. The mean percentage changes in BMD from baseline to 6 and 12months were significant (2.85% increase, p